Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare and severe chronic disease characterized by recurrent chronic eczema (with erythematous, scaly and crusted lesions) mainly affecting seborrheic areas (e.g. scalp, forehead, eyelids, paranasal and periauricular skin, neck, axillae, and groin), a generalized fine papular rash, chronic nasal discharge with crusting of the anterior nares, and non-virulent Staphylococcus aureus or beta-hemolytic Streptococcus infections, thought to be a result of HTLV-1-induced immunosuppression. Lymphadenopathy, anemia, mild to moderate pruritus and increased incidence of other infections (e.g. crusted scabies) have also been reported in some patients. Patients may subsequently develop other HTLV-1 associated conditions such as adult T-cell leukemia/lymphoma and tropical spastic paraparesis.
Biomarker and diagnostic research for infective dermatitis associated with HTLV-1 has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for infective dermatitis associated with HTLV-1.
48 publications have been identified in PubMed for infective dermatitis associated with HTLV-1. Research spans Basic Science / Preclinical (35%), Diagnostic / Biomarker (25%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 17 | 35% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:32 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Testing and diagnosis research
12 |
25% |
Research summaries | 7 | 15% |
Disease patterns and progression | 5 | 10% |
Patient case studies | 3 | 6% |
New treatment approaches | 3 | 6% |
Clinical study results | 1 | 2% |
Oikawa JT (2026). [PMID: 42134714](https://pubmed.ncbi.nlm.nih.gov/42134714/). *Acta Trop*. [Epidemiology / Natural History]
Youssef G (2026). [PMID: 41397912](https://pubmed.ncbi.nlm.nih.gov/41397912/). *Neuro Oncol*. [Diagnostic / Biomarker]
He J (2026). [PMID: 41525854](https://pubmed.ncbi.nlm.nih.gov/41525854/). *Pharmacol Res*. [Review / Meta-Analysis]
Leelatian N (2026). [PMID: 40887772](https://pubmed.ncbi.nlm.nih.gov/40887772/). *Neuro Oncol*. [Diagnostic / Biomarker]
Brand F (2026). [PMID: 41546701](https://pubmed.ncbi.nlm.nih.gov/41546701/). *Acta Neuropathol*. [Epidemiology / Natural History]
Macarulla T (2026). [PMID: 41940135](https://pubmed.ncbi.nlm.nih.gov/41940135/). *EJC Suppl*. [Gene Therapy / Novel Therapeutics]
Yao ZG (2026). [PMID: 41782063](https://pubmed.ncbi.nlm.nih.gov/41782063/). *Acta Neuropathol Commun*. [Basic Science / Preclinical]
Gupta P (2026). [PMID: 41953006](https://pubmed.ncbi.nlm.nih.gov/41953006/). *Front Immunol*. [Basic Science / Preclinical]
Garrido-Pinzás G (2026). [PMID: 41729993](https://pubmed.ncbi.nlm.nih.gov/41729993/). *PLoS Negl Trop Dis*. [Epidemiology / Natural History]
Wan J (2026). [PMID: 41460204](https://pubmed.ncbi.nlm.nih.gov/41460204/). *Clin Cancer Res*. [Basic Science / Preclinical]